Buparlisib (BKM120, NVP-BKM120)

目录号：S2247

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 2227.95	现货
5mg	RMB 1400.12	现货
10mg	RMB 2607.65	现货
50mg	RMB 7928.28	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献42篇：

Science, 2019, 364(6441)

PubMed: 31097636 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Cell, 2017, 161(4):803-16

PubMed: 25913192 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163

PubMed: 28119489 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(3):644-56.

PubMed: 26224873 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):113

PubMed: 27765055 ( click the link to review the publication )

PLoS One, 2016, 10.1371/journal

PubMed: 27055253 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

J Clin Invest, 2015, 10.1172/JCI78018

PubMed: 25798617 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.173

PubMed: 25982275 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 60C:34-42

PubMed: 25578563 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Immunol Res, 2015, 10.1007/s12026-015-8648-y

PubMed: 25869396 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

J Exp Med, 2014, 211(13):2497-2505

PubMed: 25488980 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1265-70

PubMed: 25176649 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(1):R9

PubMed: 24451154 ( click the link to review the publication )
Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1520-31

PubMed: 25103499 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108780

PubMed: 25360799 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101969

PubMed: 25003333 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):186-99

PubMed: 24302555 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(21):5940-51

PubMed: 23918606 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.509

PubMed: 24292683 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R55

PubMed: 23844554 ( click the link to review the publication )

BMC Cancer, 2013, 13:465

PubMed: 24103747 ( click the link to review the publication )

University Gattingen, 2013, Elisabeth Hand

PubMed: ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

特性

BKM120是可用于口服的生物有效的PI3K抑制剂。

靶点

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	点击更多
52 nM	116 nM	166 nM	262 nM	2.4 μM	点击更多

体外研究

BKM120作用于解除PI3K调节的细胞系，包括A2780, U87MG, MCF7和DU145时，具有抗增殖活性，GI50为0.1-0.7 nM。^[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡，导致G1期细胞增多，S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡，且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。^[2]BKM120作用于人类胃癌细胞系，降低mTOR下游信号，具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系，可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞，诱导凋亡，具有协同效应，但是作用于KRAS野生型细胞没有这种效果。^[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF7	Mo\KR5l1d3SxeHnjJGF{e2G7		NEPPUVk4OiCq	M{XrTWROW09?	MlKyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?=	NHu0RYQzPDlyMEK2Oi=>
DU145	NXm2TIdFS3m2b4TvfIlkKEG\|c3H5		NI\jW3Q4OiCq	MWDEUXNQ	MkCwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N\|Uh\|ryP	MoGwNlQ6ODB{Nk[=
A2780	NF2z[YdEgXSxdH;4bYMhSXO\|YYm=		NH:y[mI4OiCq	NXzJOm5MTE2VTx?=	NH7q[olEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN	M1fGO\|I1QTByMk[2
U87MG	M1\PdWN6fG:2b4jpZ{BCe3OjeR?=		NGm2epY4OiCq	NV[0SVA1TE2VTx?=	MmH6R5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?=	M3npXFI1QTByMk[2
A2780	MmfJSpVv[3Srb36gRZN{[Xl?		MlfrNUBp	MYrEUXNQ	MWjJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>?	M3fKUlI1QTByMk[2
DU145	NU\aUY06TnWwY4Tpc44hSXO\|YYm=		NIjhO5UyKGh?	NWS2e4xwTE2VTx?=	NVf1fnBEUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKESXMUS1JINmdGy\|IHjhdoJwemmwZzDMT2IyKG23dHH0bY9vKHerdHigSWM2OCCxZjCwMlA4OyEQvF2=	M13lRVI1QTByMk[2
A2780	MXzGeY5kfGmxbjDBd5NigQ>?		NHPWZXgyKGh?	Mn;3SG1UVw>?	M4e5fmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO\|Qh\|ryP	NGjPR48zPDlyMEK2Oi=>
MCF7	MoLmSpVv[3Srb36gRZN{[Xl?		NIq3SXEyKGh?	MV3EUXNQ	Ml31TY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiRUW0OWshdXW2YX70MY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGg{txO	NV;xUI5ZOjR7MECyOlY>
U87MG	MkXNSpVv[3Srb36gRZN{[Xl?		M{nmdVEhcA>?	NGTWc3RFVVOR	NXO3RXpbUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?=	NEm2[2ozPDlyMEK2Oi=>
A2780	M3SxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXO3NkBp	M131UmROW09?	NWm0VYk5TUN3ME2wMlUzKM7:TR?=	NF;4VWczPDlyMEK2Oi=>
SKMES-1	MmXFR5l1d3SxeHnjJGF{e2G7	MWKxJO69VQ>?	M{TRTlczKGh?		NX3tXnNiUW6mdXPld{Bk\WyuIHTlZZRp	MUOyOlAyOzNzOB?=
H596	M17IZWZ2dmO2aX;uJGF{e2G7	MYqxJO69VQ>?			NInhU3hKdXCjaYLzJINmdGxibXnndoF1cW:w	M3PYXVI3ODF\|M{G4
HCC2450	MlPZSpVv[3Srb36gRZN{[Xl?	MXexJO69VQ>?			MlHMTY1x[Wm{czDj[YxtKGmwdnHzbY9v	NVTaO\|BoOjZyMUOzNVg>
A549	MkK0SpVv[3Srb36gRZN{[Xl?	M4\m[\|UxOCCwTR?=	MWC0PEBp	NUXtNYJtTE2VTx?=	NX3RRppmUW6qaXLpeJMhSWu2IHHjeIl3[XSrb36=	MX2yOVk{PzJ7OR?=
A549	NHPJNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37NWFEh\|ryP	MmLlO\|IhcA>?	NF;iZZZFVVOR	MWPJcohq[mm2czDj[YxtKGe{b4f0bC=>	M3HSTlI2QTN5Mkm5
H522	NWnGUXk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoqyNUDPxE1?	NH;KeY84OiCq	MnfzSG1UVw>?	MnnkTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NWHOXFFLOjV7M{eyPVk>
LNCaP	MWnGeY5kfGmxbjDBd5NigQ>?	NEe5TWIyKM7:TR?=			MnXhV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN?	NI\tdnQzPTN4MEe5PS=>
LNCaP95	MWjGeY5kfGmxbjDBd5NigQ>?	M1HWdlEh\|ryP			M2jiSnN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy\|	NWX0cmxnOjV\|NkC3PVk>
HCT-15	M4jqT2Fxd3Sxc3nzJGF{e2G7	MnrNNVAh\|ryP	NWPtPFd2PDhiaB?=	MVvEUXNQ	MUjJcoR2[2W\|IHHwc5B1d3OrczDpckBJS1RvMUWgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>?	NHfLWGMzPTF3MkK0OS=>
HCT-116	M1rZWWFxd3Sxc3nzJGF{e2G7	MWWxNEDPxE1?	MX:0PEBp	M{jFfGROW09?	MUfJcoR2[2W\|IHHwc5B1d3OrczDpckBJS1RvMUG2JINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	M2Tic\|I2OTV{MkS1
NCI-H460	NELzW3RCeG:2b4Ppd{BCe3OjeR?=	NXrBXJRYOTBizszN	MYC0PEBp	NVLO[\|dwTE2VTx?=	MlXjTY5lfWOnczDhdI9xfG:\|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	NFPUZ\|UzPTF3MkK0OS=>
SKOV-3	NWjHPYV6SXCxdH;zbZMhSXO\|YYm=	MVOxNEDPxE1?	MX60PEBp	Mnu4SG1UVw>?	MkDPTY5lfWOnczDhdI9xfG:\|aYOgbY4hW0uRVj2zJINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	NF3WXFUzPTF3MkK0OS=>
BSY-1	MlTORZBwfG:\|aYOgRZN{[Xl?	MkDoNVAh\|ryP	NFnSOWI1QCCq	NIGybolFVVOR	MknTTY5lfWOnczDhdI9xfG:\|aYOgbY4hSlO\LUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>?	NXvid4NYOjVzNUKyOFU>
MKN-1	NVzYOW42SXCxdH;zbZMhSXO\|YYm=	NVnqRnJLOTBizszN	M3zhRlQ5KGh?	MnfCSG1UVw>?	M2XK[2lv\HWlZYOgZZBweHSxc3nzJIlvKE2NTj2xJINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	NFPiOogzPTF3MkK0OS=>
NCI-H522	M37JTGFxd3Sxc3nzJGF{e2G7	MkDnNVAh\|ryP	NX3qdXdOPDhiaB?=	MYLEUXNQ	MXTJcoR2[2W\|IHHwc5B1d3Orcx?=	NHfiWnkzPTF3MkK0OS=>
OVCAR-3	NHLYUm9CeG:2b4Ppd{BCe3OjeR?=	M3LoTlExKM7:TR?=	NETaboY1QCCq	NHLCfG1FVVOR	MWHJcoR2[2W\|IHHwc5B1d3Orcx?=	M2Dq[VI2OTV{MkS1
HBC-5	M4eySmFxd3Sxc3nzJGF{e2G7	MlKxNVAh\|ryP	NFjQb3U1QCCq	NYLDPYg2TE2VTx?=	M4SzeWlv\HWlZYOgZZBweHSxc3nz	NUfYU4RMOjVzNUKyOFU>
RXF-631L	NXX6UJlYSXCxdH;zbZMhSXO\|YYm=	MX2xNEDPxE1?	MkSyOFghcA>?	M2XwbWROW09?	M4LxeGlv\HWlZYOgZZBweHSxc3nz	M{fy[VI2OTV{MkS1
MKN-45	NUOybFI{SXCxdH;zbZMhSXO\|YYm=	MYGxNEDPxE1?	NGjrcHU1QCCq	NWrSNXY5TE2VTx?=	NH\E[XZKdmS3Y3XzJIFxd3C2b4Ppdy=>	NUfzSYZ[OjVzNUKyOFU>
BON-1	M36zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUS1NFAhdk1?	NXzuSIU2OTBiZB?=	NYrHfY5PTE2VTx?=	NIjwNmRKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	NHO5[3MzPTB{NkK5Ni=>
BON-1	NGH2[YJHfW6ldHnvckBCe3OjeR?=	NWLjdZZJPTByIH7N	MlrROEBp	M{TQPGROW09?	MmLuTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?=	NHfUcVczPTB{NkK5Ni=>
QGP-1	NITHNYNHfW6ldHnvckBCe3OjeR?=	MnjGOVAxKG6P	MmfiOEBp	NGXYeFRFVVOR	NXj1SZBIUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ\|MEigZY5lKFOnckS3Ny=>	Ml\GNlUxOjZ{OUK=
Huh7	NGP2PW1HfW6ldHnvckBCe3OjeR?=	MX[xJO69VQ>?	MXqxJIg>	MlfTSG1UVw>?	NX3IUnRCUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJ2N{S=	NYfV[ZBnOjVyMES0NFM>
BNL	MkjjSpVv[3Srb36gRZN{[Xl?	M3P1OVEh\|ryP	MkTSNUBp	M3\EN2ROW09?	MmTITY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJHM3	M3;3dlI2ODB2NECz
MDA-MB-175	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELBdJAyKM7:TR?=	NITrZ4o2KGR?	Mn\uSG1UVw>?	MnnoTWM2ODxzIN88US=>	NGPqS3YzPDh5OUe5Oi=>
MDA-MB-134	MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDQUXZLOSEQvF2=	NGPTWHc2KGR?	NE\GcZVFVVOR	NWDSdZJXUUN3MEyxJO69VQ>?	MkHONlQ5Pzl5OU[=
HCC1500	NVT6N4JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HJSVEh\|ryP	NH7EUIE2KGR?	NFeyU\|ZFVVOR	NUfMSlJPUUN3MEyxJO69VQ>?	NGDrVGwzPDh5OUe5Oi=>
EFM-19	M3Lrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\4ZVEh\|ryP	NEDNdoc2KGR?	NEfVT5hFVVOR	NF[0b2ZKSzVyPEGg{txO	MlS4NlQ5Pzl5OU[=
ZR-75-30	M3jvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13JfVEh\|ryP	MXO1JIQ>	NILCbHRFVVOR	NHjqfGNKSzVyPEGg{txO	M4PWeVI1QDd7N{m2
MDA-MB-361	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvxbIkyKM7:TR?=	MY[1JIQ>	NIDibWNFVVOR	NEnZdlJKSzVyPEGg{txO	Mk\VNlQ5Pzl5OU[=
T-47D	NH\ZOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUCxJO69VQ>?	NWDERVVDPSCm	MULEUXNQ	NEfzTmZKSzVyPEGg{txO	MV[yOFg4QTd7Nh?=
SK-BR-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLET3dDOSEQvF2=	NV;nXXRRPSCm	MkLnSG1UVw>?	NVuzcHJtUUN3MEyxJO69VQ>?	NGjCT\|IzPDh5OUe5Oi=>
UACC-732	M2DSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\oNUDPxE1?	NWq0fIltPSCm	NWDvTJBWTE2VTx?=	M3;Zb2lEPTB:MTFOwG0>	NFT2cnIzPDh5OUe5Oi=>
BT-474	M4XyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnPTZoyKM7:TR?=	MYC1JIQ>	NIPoU3pFVVOR	M4\TPGlEPTB:MTFOwG0>	MVqyOFg4QTd7Nh?=
HCC202	Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDiPWQyKM7:TR?=	NVj3Z4Y4PSCm	NFHDOnRFVVOR	MV;JR\|UxRDFizszN	MWiyOFg4QTd7Nh?=
MCF7	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYP1WpM5OSEQvF2=	Ml71OUBl	MYXEUXNQ	MWHJR\|UxRDFizszN	MUSyOFg4QTd7Nh?=
MDA-MB-415	NGjpeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTpS4d7OSEQvF2=	MXm1JIQ>	MVrEUXNQ	NGXOR3VKSzVyPEGg{txO	NGfBXYUzPDh5OUe5Oi=>
MDA-MB-453	NEXqdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHPe\|NzOSEQvF2=	NE\LRmo2KGR?	Mn\TSG1UVw>?	MmrqTWM2ODxzIN88US=>	NVHR[3J1OjR6N{m3PVY>
ZR-75-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nOeVEh\|ryP	M{GxNVUh\A>?	M3rqb2ROW09?	NV;F[lRbUUN3MEyxJO69VQ>?	NYfae41FOjR6N{m3PVY>
HCC38	NYP4[mt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX6xJO69VQ>?	MVu1JIQ>	MnLZSG1UVw>?	Mm[yTWM2ODxzIN88US=>	NXfmT3loOjR6N{m3PVY>
HCC1419	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP2NnEyKM7:TR?=	M1zhcFUh\A>?	MUDEUXNQ	MlvGTWM2ODxzIN88US=>	NFK2ToczPDh5OUe5Oi=>
UACC-812	MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX6xJO69VQ>?	M1\U[VUh\A>?	M1v4OGROW09?	M{LoRmlEPTB:MTFOwG0>	M3fJV\|I1QDd7N{m2
HCC1187	M37FTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rKfVEh\|ryP	MnzROUBl	NXOyUIhbTE2VTx?=	MY\JR\|UxRDFizszN	M1z2c\|I1QDd7N{m2
KPL-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:xJO69VQ>?	M{W4UVUh\A>?	M{DrN2ROW09?	M3fVemlEPTB:MTFOwG0>	MnzNNlQ5Pzl5OU[=
SUM-225	MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYWxJO69VQ>?	NVT0d5BiPSCm	MXjEUXNQ	NHjsdlZKSzVyPEGg{txO	MoXINlQ5Pzl5OU[=
EFM-192A	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\HNUDPxE1?	NULZNnY4PSCm	NH7XVYhFVVOR	NGrzOHNKSzVyPEGg{txO	NGLjWlAzPDh5OUe5Oi=>
JIMT-1	NHnTbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfMe4oyKM7:TR?=	M3jUWlUh\A>?	NH21fVlFVVOR	NXfs[ZdQUUN3MEyxJO69VQ>?	NIjqWZAzPDh5OUe5Oi=>
HCC1143	NXXPNVUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV[xJO69VQ>?	MXq1JIQ>	NGnMbZBFVVOR	NEjFU5lKSzVyPEGg{txO	MXyyOFg4QTd7Nh?=
HCC2218	NUPBXlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPBNUDPxE1?	MlrwOUBl	MnPsSG1UVw>?	MnP0TWM2ODxzIN88US=>	Mn7WNlQ5Pzl5OU[=
MDA-MB-468	Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLKb5NOOSEQvF2=	NV\kcoNCPSCm	NYHtN\|R7TE2VTx?=	MoHrTWM2ODxzIN88US=>	NFu0ZXgzPDh5OUe5Oi=>
BT-20	NVOxcHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYCxJO69VQ>?	NY\kXGZRPSCm	M2f3[2ROW09?	M2\6XWlEPTB:MTFOwG0>	NFezSI8zPDh5OUe5Oi=>
MDA-MB-435	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFqwU3cyKM7:TR?=	MmPqOUBl	M2G2cWROW09?	NXm1OG5[UUN3MEyxJO69VQ>?	M1Trb\|I1QDd7N{m2
BT-549	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrzNUDPxE1?	MWO1JIQ>	MmrXSG1UVw>?	NILLSodKSzVyPEGg{txO	M3K5T\|I1QDd7N{m2
HCC1806	NWX2SVhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TQeVEh\|ryP	M4HNfFUh\A>?	NE\lbotFVVOR	MmLUTWM2ODxzIN88US=>	Mor3NlQ5Pzl5OU[=
HCC1937	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXlNIsyKM7:TR?=	Mmn2OUBl	NUi0fG5XTE2VTx?=	MlnWTWM2ODxzIN88US=>	NWjDbIIxOjR6N{m3PVY>
Hs578T	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXY[W0yKM7:TR?=	NYXVfVc5PSCm	NIr1c5dFVVOR	NEnHcnhKSzVyPEGg{txO	MXmyOFg4QTd7Nh?=
LN18	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPZ[FAzOCEQvF2=	M{XZeVczKGh?	MoniSG1UVw>?	MXzJR\|UxRDVizszN	M4\2N\|I1PzRzMEe0
LN229	NVrCN286T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Xlc\|IxKM7:TR?=	NW\TUGxqPzJiaB?=	NUG5OoJRTE2VTx?=	M3m1TmlEPTB:NTFOwG0>	M{PCVVI1PzRzMEe0
LNZ308	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnRNlAh\|ryP	MkXCO\|IhcA>?	MVPEUXNQ	M1X0U2lEPTB:NTFOwG0>	NHXYN5gzPDd2MUC3OC=>
T98G	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrLNlAh\|ryP	NGrOZnE4OiCq	NEDtZXdFVVOR	NWTrVpJJUUN3MEy1JO69VQ>?	M3TqcVI1PzRzMEe0
U87	MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofWNlAh\|ryP	MVG3NkBp	NH\XXplFVVOR	MVLJR\|UxRDVizszN	MV[yOFc1OTB5NB?=
LN18	M3i5SmZ2dmO2aX;uJGF{e2G7	MYG1JO69VQ>?	NUGyS5h[OjRiaB?=	MlnZSG1UVw>?	M3jsZmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?	MX:yOFc1OTB5NB?=
LNZ308	MYPGeY5kfGmxbjDBd5NigQ>?	M3uzWFUh\|ryP	NV\Kc2pLOjRiaB?=	M3;Td2ROW09?	NHjzN5ZKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuW	NG\NOVczPDd2MUC3OC=>
Saos-2	M4DLZmZ2dmO2aX;uJGF{e2G7	MWm1NEDPxE1?	M3nhdlQ5KGh?		M3vyTWlvcGmkaYTzJINmdGxiaX72ZZNqd25?	NYrxNGg4OjR5Mke2OlA>
MG-63	MU\GeY5kfGmxbjDBd5NigQ>?	NXO1Zm1wPTBizszN	MoO1OFghcA>?		NHrycGdKdmirYnn0d{Bk\WyuIHnueoF{cW:w	M2[4RlI1PzJ5Nk[w
SJSA-1	M1;l[mZ2dmO2aX;uJGF{e2G7	NWPKeWJSPTBizszN	NYrtSpo6PDhiaB?=		MoD0TY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>?	NV2xZYVwOjR5Mke2OlA>
Saos-2	NV7NNIFqTnWwY4Tpc44hSXO\|YYm=	NWTuTZh1PTBizszN	MoHHOFghcA>?		M4noS2lvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG\|ZT2yJIV5eHKnc4Ppc44>	NEXhd28zPDd{N{[2NC=>
MG-63	MlLqSpVv[3Srb36gRZN{[Xl?	MWm1NEDPxE1?	NXjWUVBIPDhiaB?=		NY\HT\|ZLUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>?	MlTmNlQ4Ojd4NkC=
SJSA-1	MmLnSpVv[3Srb36gRZN{[Xl?	M1nvVFUxKM7:TR?=	NHPjNmU1QCCq		M1XmeGlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG\|ZT2yJIV5eHKnc4Ppc44>	MnzmNlQ4Ojd4NkC=
Saos-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTtOVAh\|ryP	M4r0SlQ5KGh?		MWnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	M2PhW\|I1PzJ5Nk[w
MG-63	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nQe\|UxKM7:TR?=	MoXhOFghcA>?		M1jnPWlvcGmkaYTzJINmdGxidnnhZoltcXS7	NVfVNm5YOjR5Mke2OlA>
SJSA-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nlfFUxKM7:TR?=	NVfjT\|hiPDhiaB?=		MXrJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	MWOyOFczPzZ4MB?=
FaDu	MoWwSpVv[3Srb36gRZN{[Xl?	NXH1ZZp3PSEQvF2=	NIrFS4ozPCCq	NX6wcllnTE2VTx?=	MYXS[YR2[2W\|IH;4fYdmdiClb37zeY1xfGmxbh?=	MojENlQ3OzFzNEe=
EMT6	NUftcJV[TnWwY4Tpc44hSXO\|YYm=	M{DOT\|Uh\|ryP	NF\jfGEzPCCq	MlfKSG1UVw>?	NHjoV\|FT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=>	NH;UXFgzPDZ\|MUG0Oy=>
HCT116	MVLGeY5kfGmxbjDBd5NigQ>?	NI\xVII2KM7:TR?=	Ml62NlQhcA>?	NGntUY9FVVOR	NIfJPHFT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=>	MXuyOFY{OTF2Nx?=
U87	M4LUdWZ2dmO2aX;uJGF{e2G7	NY[5TnB4PSEQvF2=	NGDuWJozPCCq	NFXZZlBFVVOR	M1HYOnJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	MlTPNlQ3OzFzNEe=
GBM	MWnBdI9xfG:\|aYOgRZN{[Xl?	MXiy{txO	MnizOFhp	NFrWZ2JFVVOR	MV;pcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m\|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5	MljyNlQ2ODB2OUK=
BON	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWKxMVXPxE1?	MWi3Nog>		Moqx[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=>	NIS1eoYzPDR2M{WyNy=>
BON	MmHhRZBweHSxc3nzJGF{e2G7	NUSxOnMxOS13zszN	MUWyOIg>		NF3pOFFqdmO{ZXHz[ZMh[XCxcITvd4l{	MXOyOFQ1OzV{Mx?=
H1975	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1W4e\|AvOy17LkdOwG0>	NFPSS204Omh?	MU\EUXNQ	MoDtTWM2OD1zLkO4Oe69VQ>?	MV[yOFM{Pzh2Nh?=
H1975	M2izPWFxd3C2b4Ppd{BCe3OjeR?=	NWn4bHRoOs7:TR?=	MVuyOIg>	MWXEUXNQ	M4[5VYlv[3KnYYPld{BieG:ydH;zbZMhemG2ZTDzbYdvcW[rY3HueIx6	MUOyOFM{Pzh2Nh?=
T-ALL	MV3BdI9xfG:\|aYOgRZN{[Xl?	NYrENW5M[mW2d3XlckAyNjRiYX7kJFUvOyCvTTDheEAzPGhiYX7kJFAvQSCjbnSgOU42KG2PIHH0JFQ5cCCrbjDkbYZn\XKnboSgZ4VtdCCuaX7l	MnPhNlQhd3JiNEjo	NUT4e\|A{TE2VTx?=	M2jEc4Fn\mWldIOgeIhmKFCLM1ugdIF1cHejeTDpckBVNUGOTDDj[YxtKGyrbnXz	MV[yOFMyODd\|Nh?=
BCR-ABL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4S3OFAvOjVvMUFOwG0>	MnvhOIQ>		MmrGd4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>?	NX;neJlGOjR{NES2NVI>
LC-1/SQSF	MUPGeY5kfGmxbjDBd5NigQ>?	NYribVdIO87:TR?=	MnWwNlRp	Mn36SG1UVw>?	NYO1Rop6\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt	M4rQcFI{QThyMEmz
Primary CLL cells	NHzGdJZCeG:ydH;zbZMhSXO\|YYm=	MmPiNU0yOM7:TR?=	NH3pZWg1QGh?		M4Hqd4lv\HWlZYOgZZBweHSxc3nzJIlvKEOOTDDj[YxteyCrbnTldIVv\GWwdDDv[kBxem:pbn;zeIlkKG2jcnvldpM>	NYLHVnUxOjN6NUC4NFc>
Primary CLL cells	NUnoXZBpU2mwYYPlJGF{e2G7	NF7tT5oz\|ryP	MVezNI1qdg>?		MXHk[YNz\WG\|ZXSgVGk{UyCjY4Tpeol1gQ>?	M{TrUlI{QDVyOEC3
Primary CLL cells	MmXyR5l1d3SxeHnjJGF{e2G7	MX6y{txO	NFjrfWwzPGh?		MVHpcoR2[2W\|IHPlcIwh[3m2b4TvfIlkcXS7	M3ThSlI{QDVyOEC3
human NSCLC cell lines	MWrBdI9xfG:\|aYOgRZN{[Xl?	NHThPZkxNjF{NT20{txO	NU\NeZNoOjSq	M1HhWGROW09?	NV;pWW9PUUN3MIOgdoFv\2W\|IH\yc40hOC52LUNOwG0>	NHfpSYUzOzV4MkS3Ni=>
human HCC cell lines	NYnU[olwS2WubDD2bYFjcWyrdImgZZN{[Xl?	M1flZlAvODB3LUJOwG0>	NV7kN5VDPDiq		MXLJR\|UxRTIQvF2=	MnLUNlM1QDl7OUm=
Huh7	NH3uTolMcW6jc3WgRZN{[Xl?	NHLJcFEy\|ryP	MWm0PIg>		M1f5d5Nq\26r77{BZ4FvfGy7IILl[JVk\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=>	MofoNlM1QDl7OUm=
SK-HEP1	Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnztNU0zOM7:TR?=	NHG0Um04Omh?	NV;OVmJqTE2VTx?=	MYnJR\|Ux97zeMd88US=>	MViyN\|Q4QTF\|Nh?=
786-0	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYOxMVIx\|ryP	NGDybnE4Omh?	MVvEUXNQ	MmLZTWM2OO,:nEJOwG0>	Mke1NlM1PzlzM{[=
JVM2	NH;ndW9EgXSxdH;4bYNqfHliYYPzZZk>	MYqwMlIuOjEQvF2=	MXO3Nog>	NFnROFhFVVOR	M1XaTmlEPTB;MD65{txO	NUjuc3F7OjN{M{i2N\|k>
EHEB	Mli5R5l1d3SxeHnjbZR6KGG\|c3H5	M1;j[\|AvOi1{MN88US=>	NVfaR4h2PzKq	NU\BSHJJTE2VTx?=	MY\JR\|UxRTBwN988US=>	MlvXNlMzOzh4M{m=
MEC2	MYfDfZRwfG:6aXPpeJkh[XO\|YYm=	M{G4NFAvOi1{MN88US=>	NW\z[HR{PzKq	NUGxTYtjTE2VTx?=	NGPPUWdKSzVyPUCuO:69VQ>?	NYrYWY51OjN{M{i2N\|k>
primary B-CLL lymphocytes	M{Lz[2Fxd3C2b4Ppd{BCe3OjeR?=	NVvlNWtXUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?=	MkC4NlRp	MXnEUXNQ	NYLzSlVJUUN3MP-8oFPPxE1iZn;yJIFtdCCyYYTp[Y51ew>?	MkjSNlMzOzh4M{m=
primary B-CLL lymphocytes	MYfLbY5ie2ViQYPzZZk>	MmL5TWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>?	MonINlRp		NUDIW4lKcW6qaXLpeJMheDdyU{\LJEYhPEVvQmCxJIV5eHKnc4Ppc44>	NIDSfYEzOzJ\|OE[zPS=>
human NSCLC	NVTwOZJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnLNE42NTMQvF2=	MXi3Nog>		MUPJR\|UxRTIQvF2=	MofTNlI4QDF\|OUO=
human NSCLC	MoTpT4lv[XOnIFHzd4F6	MYix{txO	NYfZ[3hEOjSq		NHH4PHBqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70	MYWyNlc5OTN7Mx?=
Y1 cell line	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHW4XpIxNjIQvF2vNe69VQ>?	M1HYdlI1cA>?	NVm4b3lUTE2VTx?=	NYDE[HVKcW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO=	M2m0blIzPjl{OUC0
PIK3CA-mutant MCF7	NWLkSHlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEmwe2hIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?=	MYW3Nog>		M{PZTGdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P	MmfrNlI3PTN7Nke=
PIK3CA-mutant MCF7	NVHkVWF{U2mwYYPlJGF{e2G7	Mn75TWM2OD1zMUVCtVNvVQ>?	NEXyOIM4Omh?		NWnWNWlTUUN3ME2xNVTDuTOwTTDpckBz\WS3Y3nu[{BCc3RicHjvd5Bpd3K7bHH0bY9vKGyndnXsdy=>	MoLDNlI3PTN7Nke=
MCF7-myr-Akt	M1X1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>?	NX3LcZZDPzKq		NFPiOWRIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?=	NVP4UIZPOjJ4NUO5Olc>
colon cancer cell lines	NYn6cVJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHT4RZMxNTFyzszN	MVy3Nog>	NYXWS3o{TE2VTx?=	MYPJR\|UxRTIQvF2=	NVvDNmhrOjJ3NEO4OVc>
gastric cancer cell lines	M2fDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPXNE0yOM7:TR?=	MmfIO\|Jp	NX\PcJhbTE2VTx?=	MULJR\|UxRTJvNd88US=>	NYPNOGFROjJ3NEO4OVc>
HCT-116/HT-29/MKN-45	MVXBdI9xfG:\|aYOgRZN{[Xl?	NFzyboIz\|ryP	NGXvUVA1QGh?		NEe3TWd{cGmodDDpckBIOiCyaHHz[S=>	M1fHOlIzPTR\|OEW3
HT-29 and HCT-116	NUjkcFRRS2G\|cHHz[UBie3OjeR?=	NYTGdo1mPc7:TR?=	NYK5[GJSOjSq		NIjLSYtqdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm=	NYroS\|B7OjJ3NEO4OVc>
MM cell lines	NYnJfZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTZWplzOTEQvF2=	MmTrNlRp	NGX3fY1FVVOR	MXHJR\|UxKH[jcnnld{BidW:wZzDkbYZn\XKnboSgZ4VtdCCuaX7ld{BqdiC2aX3lJIFv\CCmb4PlJIRmeGWwZHXuZ4U>	NEfVRWszOjJyN{S4OS=>
ARP-1	NXu0fWp1SXCxcITvd4l{KEG\|c3H5	NUTEUIdPOTEQvF2=	NGT3c3IzPGh?	MVPEUXNQ	MUfpcoR2[2W\|IF3NJINmdGxiYYDvdJRwe2m\|IITodo92\2hiY3HzdIF{\SCjY4TpeoF1cW:w	M1rOTFIzOjB5NEi1
SNU-601	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2DjT\|czcA>?	NVqwT2Y{TE2VTx?=	NV;TPFFRUUN3ME2wMlgyPsLzMD6wOlPPxE1?	MYqyNlE2QThzNB?=
SNU-1	M1Xa[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlraO\|Jp	MWjEUXNQ	MXLJR\|UxRTFwMEiyxtExNjB{ON88US=>	MmrSNlIyPTl6MUS=
SNU-668	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoDVO\|Jp	M{\2b2ROW09?	NFrwXYFKSzVyPUGuOVc6yrFyLkC3OO69VQ>?	NF3ZPFczOjF3OUixOC=>
AGS	NIW5SHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUK3Nog>	NETuXWdFVVOR	NV3tXmQ5UUN3ME2xMlcyPMLzMD6xNVfPxE1?	NInROGgzOjF3OUixOC=>
SNU-216	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUXidXExPzKq	NHv1VGFFVVOR	NWrYbZJtUUN3ME2yMlY6OsLzMD6wPFLPxE1?	NVjRdm5pOjJzNUm4NVQ>
SNU-5	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{nUOFczcA>?	MoXQSG1UVw>?	M2XEfmlEPTB;MT6zOVHDuTBwMEmx{txO	MWKyNlE2QThzNB?=
SNU-638	M{\sXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWe3Nog>	MlfESG1UVw>?	MYrJR\|UxRTJwMkiyxtExNjB3M988US=>	NXjjSFNQOjJzNUm4NVQ>
SNU-16	M1O3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGKzcXg4Omh?	NG\QXIZFVVOR	M2Cz[mlEPTB;MT61O\|PDuTBwMECx{txO	NGrRe5ozOjF3OUixOC=>
SNU-484	M3vwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXHUR3M5PzKq	NVLSRY45TE2VTx?=	MYHJR\|UxRTFwN{K4xtExNjB2Nd88US=>	Mm\LNlIyPTl6MUS=
SNU-620	M4HPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXG3Nog>	M1y0b2ROW09?	MkmxTWM2OD1{LkmzPeKyOC5yMEJOwG0>	MVSyNlE2QThzNB?=
SNU-719	NEDISoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXm3Nog>	NYC5RXJHTE2VTx?=	M3;IWGlEPTB;Mz6wN\|fDuTBwMEOy{txO	MVOyNlE2QThzNB?=
glioma cell lines	NEjqS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2n2NFczcA>?		M3iwWGlEPTB;MT2y{txO	MlS3NlIxPjVyOEC=
U87	MXnBdI9xfG:\|aYOgRZN{[Xl?	M2XoSFLPxE1?	MXi3Nog>		MUnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGGwZDDjcIVifmWmIGDBVnAh[W6mIHPhd5Bie2VvMx?=	MX6yNlA3PTB6MB?=

... Click to View More Cell Line Experimental Data

体内研究

BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤，完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型，显示抗癌活性。^[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型，导致肿瘤体积和K链水平明显降低。^[2]

激酶实验：^[2]	+ 展开 PI3K 生化实验(ATP 消耗实验): BKM120溶于DMSO中，按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT，及0.05% CHAPS)，然后加到每孔中，随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗，然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟，然后通过荧光测定残留的ATP。
细胞实验：^[1]	+ 展开 Cell lines: A2780细胞 Concentrations: 0-6.6 μM Incubation Time: 3天 Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔10³个细胞的密度接种在相同培养基上，温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中，在37^oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果 (Only for Reference)
动物实验：^[1]	+ 展开 Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠 Formulation: 15% Captisol Dosages: ~60 mg/kg Administration: 每天口服处理 (Only for Reference)

参考文献

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

+ 展开

溶解度 (25°C)

体外	DMSO	82 mg/mL (199.8 mM)
	Ethanol	2 mg/mL (4.87 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+ddH2O	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Buparlisib (BKM120, NVP-BKM120) SDF

分子量	410.39
化学式	C₁₈H₂₁F₃N₆O₂
CAS号	944396-07-0
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02756247	Active not recruiting	Lymphoma\|Mantle Cell Lymphoma\|Follicular Lymphoma\|Diffuse Large B Cell Lymphoma	Memorial Sloan Kettering Cancer Center\|Janssen Scientific Affairs LLC\|Novartis Pharmaceuticals	May 2016	Phase 1
NCT02756247	Active not recruiting	Lymphoma\|Mantle Cell Lymphoma\|Follicular Lymphoma\|Diffuse Large B Cell Lymphoma	Memorial Sloan Kettering Cancer Center\|Janssen Scientific Affairs LLC\|Novartis Pharmaceuticals	May 2016	Phase 1
NCT02614508	Active not recruiting	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT02614508	Active not recruiting	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT01613677	Withdrawn	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2
NCT01613677	Withdrawn	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

选择性强的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
选择性强的PI3K抑制剂

TGX-221 : p110β-specific, IC50=5 nM.
活性最高的PI3K抑制剂

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA批准的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
最新的PI3K抑制剂

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

研究领域

产品类型

Buparlisib (BKM120, NVP-BKM120)

客户使用Selleck该产品发表文献42篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Buparlisib (BKM120, NVP-BKM120) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品